Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic target for managing metabolic syndromes. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon output. GLP-1 peptides possess promising therapeutic outcomes in treating type 2 diabet